spacer
home > > autumn 2009 > three-dimensional advantages
PUBLICATIONS


Three-Dimensional Advantages

An ageing population and high expectations for a better quality of life in western European society have led to calls for more efficient and affordable healthcare. However, the development of new drugs and therapies has decelerated, despite the application of combinatorial chemistry and new therapeutic strategies, such as nanoparticle-based drug delivery systems (nanomedicine) (1). Although the numbers of newly developed compounds have steadily increased, regulatory approval rates are declining while attrition rates during Phase II and III clinical trials are on the rise. In other words, despite initial successful animal testing, drug failure remains high, thus putting a huge cost and time burden on pharmaceutical companies (2).

Some of the general problems associated with animal testing include those of reproducible animal growth, health status, weight, diet and method of drug administration. Additional limitations of animal testing are based on intrinsic genetic differences between rodents and humans, leading to the development of improper therapeutic strategies. As a result, efforts to develop new drugs based on data derived from animal models suffer from unreliable transition of preclinical rodent data to clinical application. However, due to the lack of alternatives and regulatory requirements, animal testing has become the model of choice for a number of medical research areas, despite its limitations.

CELL-BASED ASSAYS

One alternative to animal testing is cell-based assays. These are generally considered to be more reliable because cellular responses provide a better understanding of both the physiology of the drug target, as well as the pharmacological interaction. However, classical cell-based assays, particularly in combination with prevailing screening technologies, continue to employ cell phenotypes that differ markedly from those found in human pathology. Many studies have demonstrated that cellular phenotypes are controlled by the complex interaction between genome, proteome and the external environment. Cells regularly change by altering their output of matter and energy which, depending on its genetic makeup and environmental context, can lead to either a pathological (disease) or a normal phenotype. Furthermore, it is important to note that cells exist in vivo within three-dimensional cell communities that form tissue. These communities, or biological niches, consist of various cell types coexisting in close proximity to each other. Biological niches are influenced by various parameters, such as nutrient supply, waste removal and constant temperature. Finding the proper balance between these parameters provides a minimal stress environment, thus allowing cells to display their natural phenotypes (3). In contrast, current in vitro cell-based assays do not take into consideration the natural spacing between cells, and do not adequately control temperature and fluid stress (4).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Following the completion of his PhD in Chemistry in 2000, Peter Ertl worked as a postdoctoral fellow at the University of California at Berkeley. In 2003, he co-founded RapidLabs Inc, a diagnostic start-up company where he worked as Director of Product Development. He then joined the Division of Nano- System-Technologies at the Austrian Research Centers (ARC) in 2005 and has lectured at the Technical University Vienna since 2006. In 2009, Peter became a Senior Scientist at the Austrian Institute of Technology (AIT), where his research involves the development of LOC systems for cell analysis with special emphasis on nanotoxicology, biotechnology and medicine.

Lukas Richter has worked at the AIT for the last three years. In 2008, he successfully completed his studies in biotechnologies and received a Masters degree from the University of Applied Life Sciences in Vienna. For his thesis, he conducted research on microfluidic biochips for fungal biofilm analysis. He currently works on the development of a human capillary system on a chip capable of continuously and non-invasively monitoring cell responses to external stimuli.

spacer
Peter Ertl
spacer
spacer
spacer
Lukas Richter
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

- The biotech companies 3P Biopharmaceuticals and Toleranzia collaborate for that MG treatment - MG is an orphan disease which has a major unmet medical need and a large market potential - The drug candidate,TOL2, has already achieved several positive preclinical results
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement